Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.03, with a volume of 839,780 shares trading hands.
Mateon Therapeutics Stock Down 16.2 %
The firm’s 50 day moving average is $0.04 and its 200-day moving average is $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Articles
- Five stocks we like better than Mateon Therapeutics
- What Does Downgrade Mean in Investing?
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- What Is WallStreetBets and What Stocks Are They Targeting?
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
